Deep life sciences capital-raising expertise

For publicly traded life sciences companies, Brinson Patrick has the proven expertise to raise the capital needed to grow a business.

Driven by the vagaries of research, regulatory oversight, and the rigor and cost of clinical development, life sciences is arguably one of the most dynamic and complex of all industries, with multiple factors affecting capital requirements and funding needs.

At-the-market offerings such as Brinson Patrick’s DOCS® (Dynamic Offering of Common Stock) ATM financing facility enable life sciences companies ultimate flexibility to raise smaller amounts of cash, and to start and stop that flow as R&D or other initiatives demand.

• See how our DOCS^® ATM enabled life sciences clients to meet their goals »
• Todd Wyche dispels ATM offering myths in this interview with “Genetic Engineering & Biotechnology News” »
• Learn about our life sciences expertise and how the DOCS^® ATM can serve you. »